Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody

Scott K Kuwada1

  • 1University of Utah, Huntsman Cancer Institute, Room 3243, 2000 Circle of Hope Drive, Salt Lake City, UT 84112, USA. scott.kuwada@hsc.utah.edu

Current Opinion in Molecular Therapeutics
|March 3, 2007
PubMed